New Concepts in Breast Cancer Emerge from Analyzing Clinical Data Using Numerical Algorithms by Retsky, Michael
Int. J. Environ. Res. Public Health 2009, 6, 329-348; doi:10.3390/ijerph6010347 
 
International Journal of 
Environmental Research and 
Public Health 
ISSN 1660-4601 
www.mdpi.com/journal/ijerph 
Article 
 
New Concepts in Breast Cancer Emerge from Analyzing 
Clinical Data Using Numerical Algorithms 
 
Michael Retsky 
 
Children’s Hospital and Harvard Medical School, Karp Family Laboratories, 300 Longwood Avenue, 
Boston, MA 02115, USA; E-mail: michael.retsky@childrens.harvard.edu 
 
Received: 6 November 2008 / Accepted: 10 January 2009 / Published: 20 January 2009 
 
 
Abstract:  A small international group has recently challenged fundamental concepts in 
breast cancer. As a guiding principle in therapy, it has long been assumed that breast cancer 
growth is continuous. However, this group suggests tumor growth commonly includes 
extended periods of quasi-stable dormancy. Furthermore, surgery to remove the primary 
tumor often awakens distant dormant micrometastases. Accordingly, over half of all 
relapses in breast cancer are accelerated in this manner. This paper describes how a 
numerical algorithm was used to come to these conclusions. Based on these findings, a 
dormancy preservation therapy is proposed. 
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1. Introduction: Breast Cancer Research Challenges Conventional Theories 
 
Over the past 11 years, my colleagues and I have published a series of over 30 papers that have 
challenged well-established theories in breast cancer. In collaboration with Romano Demicheli, MD, 
PhD, of Milan National Cancer Institute, we proposed in 1997 that in order to fit relapse data, breast 
cancer growth includes periods of temporary dormancy [1, 2]. Furthermore, we proposed that surgical 
removal of a primary tumor kick-starts growth of dormant distant single malignant cells and avascular 
micrometastases. These are large effects. Over half of all breast cancer relapses seem to be accelerated 
due to these mechanisms. In additional collaboration since 2000 with William Hrushesky, MD, now at 
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University of South Carolina, it has been shown that the earliest relapses (i.e., within 10 months of 
surgery for patients untreated with adjuvant chemotherapy) occur in 20% of premenopausal-node-
positive patients [3-5]. 
These theories were proposed to explain a bimodal relapse pattern which was initially reported in 
two databases and has now been identified in 13 independent databases [6-17]. This bimodal pattern 
strongly implies that there is more than one mode of relapse. Our theories propose that the first peak of 
relapses are events that are iatrogenic, i.e., triggered by surgery and that the second relapse peak 
represents the natural history of the disease.  
Figure 1 shows the Milan data, together with our explanation of the various relapse modes. The first 
peak is clearly dominant and includes two previously unreported relapse modes. The earliest relapses 
(within 10 months of surgery) are avascular micrometastases that are induced into angiogenesis by 
surgery. The relapse events in the remainder of the first peak are the result of single dormant malignant 
cells that are induced into division by surgery and then pass through angiogenesis stochastically. 
Mechanisms proposed for this first peak are growth factors produced in response to surgical wounding 
and also reduction of antiangiogenic factors due to removal of the primary tumor. After a nadir at 50 
months, the second peak that extends out to 200 months is seen. This second peak is the natural history 
of the disease. Events in the second peak are the result of stochastic transitions from one state to the 
next in the growth progression as proposed. The top of the second peak marks the point at which the 
benefits of surgical removal of the primary tumor are first seen. Until that time, surgery has produced 
accelerated relapses.  
 
Figure 1. Data from Milan are shown in raw form as number of relapse events in 10-
month wide bins. Also indicated are the various modes of relapse that are predicted by the 
computer simulation.  
 
 
The outlines of our algorithmic approach are shown in Figures 2 and 3. The three necessary 
ingredients needed to perform an algorithmic study are shown symbolically in Figure 2. First there are 
the clinical data from the Milan National Cancer Institute on follow-up of 1,173 patients after removal Int. J. Environ. Res. Public Health 2009, 6          
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of the primary tumor. The growth model chosen allows the possibility, but does not insist that tumor 
growth can be interrupted for variable periods of time at the single cell level and also before 
angiogenesis occurs. This growth model is the sum and substance of the assumptions in this project. 
The third ingredient is a stochastic computer simulation.  
 
Figure 2. Overview of the algorithmic approach to the analysis of the Milan database. 
 
 
The computer program used to determine numerical values of growth rates and transitions from 
state to state is shown as a flow chart in Figure 3. It is meant to simulate the full history of early stage 
breast cancer for a large cohort of subjects. In the simulation, breast cancer starts with one malignant 
cell in the primary tumor. The primary is allowed to grow. Once the primary has exceeded 
approximately 1 mm diameter and until it is detected and removed, metastatic cells are shed into 
distant sites where they lodge and grow until one is detected as a metastatic relapse. The shedding 
process occurs most strongly for patients with a high risk of relapse such as having positive lymph 
nodes. As the primary tumor gets larger, more metastatic cells are disseminated. Thus the risk of 
relapse also increases with the size of the primary tumor at detection, consistent with clinical data. For 
some patients, there are no metastatic cells shed and obviously they never relapse. Dormancy of 
micrometastases is allowed but not required at the single cell state and also prior to angiogenesis. 
Metastatic shedding and exits from dormancy are simulated as stochastic events. This process is 
conducted for 2,500 separate individual cohorts. Using a population this size produces reasonable 
repeatability of results. Not coincidentally, large clinical trials have approximately that number of 
subjects. The single most important result was that transitions needed to be temporarily augmented at 
the time of surgery in order to explain the first peak in the bimodal data. Results of using this 
algorithm are summarized in Figure 4. 
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Figure 3. The computer program that was used to determine numerical values of growth 
rates and transitions from dormancy is shown in flow chart form.  
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We reported in 2001 that surgery-induced angiogenesis (as first proposed by Judah Folkman 30 
years ago, in order for a tumor to grow beyond a mm or so, a blood supply needs to be provided by the 
host; this process is called angiogenesis.) quantitatively explains the so-called mammography paradox 
for women aged 40–49. That is, when mammography was first tested in randomized controlled clinical 
trials, women aged 50–59 showed an early appearing 20–30% mortality benefit. However, when this 
was evaluated in women aged 40–49, there was a counterintuitive early disadvantage that eventually 
turned into the expected advantage after 6–8 years. Most of the patients in these early trials were not 
treated with adjuvant therapy. The 2001 paper quantitatively showed how surgery-induced 
angiogenesis based on the Milan data agrees with the timing and magnitude of the mammography data. 
The most recent trial of mammography for women aged 40–49 showed a non-significant advantage at 
10 years into the trial [18] whereas there is significant advantage for women aged 50–59. So even with 
modern adjuvant therapy, early detection apparently works better for women aged 50–59 than it does 
for women aged 40–49. Women are now screened starting at age 40 in the US, while in most of 
Europe it starts at 50.  Int. J. Environ. Res. Public Health 2009, 6          
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We further proposed in 2004 that surgery-induced angiogenesis explains why adjuvant 
chemotherapy works the best by far for premenopausal-node-positive patients. NIH Consensus reports 
both in 1980 and in 1985 suggest that adjuvant chemotherapy is useful for premenopausal patients with 
positive nodes. According to our theory, sudden induced tumor growth after surgery results in a 
chemosensitive period just at the time when adjuvant chemotherapy was empirically found to be most 
effective. Two papers from 2004 on this subject have been downloaded over 25,000 times [19, 20]. 
Co-authors in one of these papers are Gianni Bonadonna, who was a key pioneer in using 
chemotherapy 30 years ago, and Judah Folkman, who founded the field of tumor angiogenesis. 
 
Figure 4. Results of computer simulation of Milan database. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A recent paper with surgeon Michael Baum reported that it was known 2000 years ago by 
premodern “chirurgeons” that surgery to remove a tumor could speed up relapses [21]. Our most 
recent work includes Nigerian surgeon Isaac Gukas, MD, PhD, as another collaborator. We suggest 
that the excess breast cancer mortality of African-Americans can partially be explained by surgery-
induced angiogenesis, since the average age of diagnosis of African-Americans is 46 years compared 
to 57 years for European-Americans [22]. This excess first appeared in the 1970s when mammography 
began. So in view of our explanation of why early detection works better for postmenopausal women 
than it does for premenopausal women, and that black breast cancer is usually premenopausal while 
white breast cancer is postmenopausal, it should be no surprise that an excess in breast cancer 
mortality began when mammography was introduced.  
The really unusual part of this story is that I have no formal background in biology or medicine. 
Rather, my background is in experimental physics. (Dr. Demicheli also has a background in physics.) 
How I became a breast cancer researcher and how the use of traditional tools from physics including 
numerical algorithms came to play a key role is a very interesting story and I enjoy telling it. I do not 
know if my unorthodox career pathway can serve as a template for future researchers, but let me 
document this story and perhaps some scientist in the future will be inspired to do something similar or 
at least know what to expect. 
First (dominant) peak (0-40 months) composed of two previously unreported surgery-
induced relapse modes. 
* Dormant single cells induced to divide and then stochastically vascularize (18 - 40 
months peak). 50% to 80% of relapses (depending on tumor size) accelerated by one 
year on average. 
* Dormant avascular micrometastases induced to vascularize (10 or less months) 20% of 
premenopausal node-positive patients. 5:1 node-positive to node-negative, 2:1 pre- 
compared to postmenopausal. Acceleration average two years.  
 
Second peak (50-200+ months) is the natural history of breast cancer. 
* The top of the second peak (60 months) marks when the advantage of surgery first 
appears (depletion of new metastases). Int. J. Environ. Res. Public Health 2009, 6          
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2. What Are the Skills and Research Culture of Experimental Physics That Might Apply to 
Cancer Research? 
 
For many scientists who chose to pursue an experimental science profession, their PhD thesis 
project was a formative educational activity where a full experiment was done, from conception to 
publication of final results of original research, under the watchful eye of a knowledgeable and 
experienced professor. The mentor’s style and strategy usually imprint on the student and form the 
basis of future research. Thus, to best describe my research skills and methodology, I am going to 
discuss my doctoral thesis project at the University of Chicago in the Physics Department under the 
guidance of Prof. Albert Crewe. 
Prof. Crewe originally worked with particle accelerators in the UK. He was renowned for 
developing a method and building equipment to extract proton beams from the accelerator for use in 
the experiments. His scientific strength was best demonstrated when he was given a new problem to 
solve. It could be almost anything in the physical sciences. He would sit at a desk with a few sheets of 
high-quality white paper and a fountain pen and calculate the likely result of various possible ideas that 
might address the problem. With his excellent knowledge of basic physics and material science, he 
could calculate almost anything within a factor of 2 in a very short time. Physics is a science with a 
strong computational basis. There are a handful of very basic equations and a mathematical hierarchy 
that allow almost everything to be calculated from fundamental principles. Most physicists could 
calculate various effects quite well in their field given enough time, access to libraries and computers. 
Crewe could do it without those tools. He could discard inferior ideas and identify good ideas rapidly 
and with reasonable accuracy. 
Once in an airplane, he began to think about electron microscopes. From a scientific aspect, that 
was not too far from particle accelerators. On that journey, he invented a new method of electron 
microscopy which might image and identify single atoms in DNA, so that perhaps the biological code 
could be read on individual DNA molecules. Electron microscopy had reached an impasse in 
resolution that could be traced in large measure to the electron sources used which were very hot 
pieces of tungsten that essentially boiled off electrons that could then be accelerated and focused. The 
main difficulty was that high aberrations resulted from the spread in energy of these hot electrons. 
Crewe deduced that room temperature electrons would be needed. One way to produce a beam of 
electrons from a cool substrate would be to chemically etch thin wires to form very sharp points. Then 
with a high electric field, cold electrons could be pulled off and used to form a beam. This source 
would be bright and could conceptually be focused to a very small size since the source has relatively 
small size. 
The problem was that a whole new technology was needed to learn how to reliably make these new, 
very delicate electron sources, learn how to use them and to build a microscope to form a very sharp 
focus. Before I got accepted into the Crewe Laboratory, they had already built a microscope that 
operated at 30 kV and produced some famous pictures of what they thought were single atoms of 
uranium [23]. We later determined that these were clumps of atoms rather than single ones. My project 
was to build the second-generation microscope that supposedly would solve many of the problems 
found in the original design and operated at higher voltage of 50  kV. Theoretically, resolution 
improved with higher voltage but design and high voltage breakdown problems were harder.  Int. J. Environ. Res. Public Health 2009, 6          
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As per Crewe’s style, designs were done based on calculations completed before starting any 
machine shop fabrication. Everything possible was calculated beforehand. Nothing was done by a trial 
and error or “seat-of-the-pants” method. My main contribution to the technology was in building the 
highly stable current supplies for the magnetic lenses and high voltage supplies [24]. My supplies were 
stable to one part per million per hour, which was 10-fold better than anything previously done. This 
stability was needed for the unprecedented resolution for which we were aiming.  
I eventually got the 50 kV microscope to the highest resolution possible for that particular design 
which was 0.24 nm and ultimately limited by the Uncertainty Principle. Using the microscope, I could 
reliably distinguish a single silver atom from a single uranium or mercury atom but could not 
distinguish a mercury atom from a uranium atom [25]. Crewe’s original motivation—to read the DNA 
code—ultimately did not work out because the electron beam caused too much damage to the DNA 
molecule [26]. Experimental science even when done properly sometimes does not work as planned. 
 
3. The Scientific Method and Models As Used in Physics 
 
It is often taken for granted, but we owe much of the enormous advance in scientific knowledge 
gained in the past few centuries to the careful and rigorous application of the scientific method. Before 
implementation of this method, for their own reasons, religious or state leaders could arbitrarily 
proclaim what was and what was not scientific truth. As an example of how this can interfere with 
science, consider the famous Galileo episode. 
In 1610, the Italian Galileo was the first to observe the moons of Jupiter and the phases of Venus 
with an early telescope. On the basis of these as well as observations of tides, he promoted the 
Copernicus theory that the earth revolved around the sun rather than the accepted Ptolemaic theory that 
planets and the sun circled a fixed earth. He was sentenced to imprisonment in 1633 (later commuted 
to house arrest) for heresy. The center of science then shifted from Italy to Northern Europe and the 
British Isles. (Newton did his work in the late 1600s.) 
Comparing that disruptive change with the more orderly abandonment of the ether theory as the 
medium in which light propagated, this was as important as the Galileo incident. Since light is a wave 
and all observed waves produced oscillations in some media, it was held that there must be a medium 
called ether in free space. The vibrations of ether would allow light to travel. Michelson and Morley 
(1887) showed that the speed of light was invariant of the direction of light propagation relative to the 
direction of earth’s travel through space. The experimental uncertainty was 10 km/s and the earth’s 
speed in its orbit is roughly 30 km/s. It was difficult to reconcile this experiment with the ether theory. 
The theorists dragged their heels trying to reinterpret these data according to their ether theory but the 
experimentalists eventually prevailed. This paved the way for Einstein to propose his theory of special 
relativity in 1905 which was dependent on the invariance of the speed of light. This theory is 
considered to be the beginning of modern physics. 
In its most basic form, the scientific method is a continual comparison of theory and experiment. 
Theoreticians propose theories that explain existing data and experimentalists perform experiments to 
test existing theories. A good theory must explain a wide variety of data based on only a few arbitrary 
assumptions and it must be testable. Of utmost importance in this relationship, when there is 
disagreement between experimental results and theoretical predictions, it is theory that must yield. It Int. J. Environ. Res. Public Health 2009, 6          
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does not matter whose theory it is or how long it has been accepted. When new data disagree with 
prevailing theory, the theory must be called into question. New theories are then proposed to explain 
these new data. In turn, further experiments are done to test the new theories. This process continues 
until theories and experiments are in accord. At that time, the theory is accepted as a valid explanation 
of the phenomenon. 
While we would like to think that it is, this process is not as rigorously practiced in medicine. The 
problem stems in part from the lack of freedom, due to ethical restrictions, to perform key experiments 
to test a theory. An additional problem is that in some chronic diseases such as breast cancer, the long 
term of the disease process is daunting. Consider the practical problems in breast cancer research. 
Researchers and physicians are trying to formulate theories and empirically optimize therapies for a 
disease that takes 15 or more years to run its course. Imagine trying to tune the engine of your vintage 
sports car if there were a 15-year period between adjusting the carburetor and waiting for the engine to 
respond. 
In cases when experiments are impractical or impossible, researchers often resort to models. Models 
are acknowledged imperfect representations of the system that you want to study but for one reason or 
another cannot be freely experimented upon. Physicists are accustomed to this, since they have long 
dealt with systems that are too distant, too hot, too cold, too fast, too long ago, too small, etc. They 
have developed very sophisticated computational models that can be used to develop theories and to 
compare theoretical and experimental results. The sophistication of modern mathematical or computer 
models can be so profound that they are sometimes considered to be equivalent to an experiment. 
Imagine that they know what happens in a supernova stellar explosion or, in a more sinister 
application, how to design an atomic weapon by using computer models. A problem that occurs while 
utilizing models is that the differences between the model and the system to be represented should be 
quite well understood and acceptable. Otherwise, results of the model may be misleading and the 
actual system may not respond as predicted by the model. 
 
4. Models As Used in Cancer Research 
 
There are two important cancer models that I want to discuss—the experimental animal model of 
tumor growth and the Gompertzian equation used as a tumor growth law. 
The common model of cancer in the laboratory is the animal model. As shown in Figure 5, this 
tumor starts as an erratic spontaneous tumor in an animal or human and is passaged many times 
usually through immune compromised animals until by selection for the most robust and rapidly 
dividing cells, it is a reliable and reproducible entity suitable for experimentation [27]. The process of 
developing such a model produces a tumor that reliably doubles in volume in a few days and does not 
exhibit dormancy. That is approximately as fast as a cell can divide. Since a detectable size 1 cc tumor 
consists of a billion cells, more or less, and 1 billion is approximately 2
30, it takes only 30 doublings or 
a few months to grow a tumor from one cell to a detectable tumor. Thus, an experiment can be done in 
a reasonable time frame for a research grant and one can reliably compare results from one laboratory 
to another anywhere in the world. All cells are constantly dividing in such a tumor. However, a human 
breast cancer has average doubling times of approximately 100 days, i.e., roughly two orders of 
magnitude slower than animal models. There are also periods of time, sometimes years in length, when Int. J. Environ. Res. Public Health 2009, 6          
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a breast tumor does not increase in size. How else can we explain relapses that can occur 10 or 20 
years after primary removal and differ little from earlier relapses other than when they occur? Or, 
indeed, how else can one explain all the reports of dormancy especially in breast cancer [28-40]? Thus, 
the much-used animal model is quite different from the breast cancer system that it is meant to 
represent. This difference has not been fully appreciated. In fact, it has only very recently been 
acknowledged that dormancy exists in cancer and needs to be considered. This was recently 
highlighted in a Cell Cycle editorial as the dormancy “problem” [41]. As an indication of the potential 
importance, it has been experimentally shown that dormant cancer cells are highly refractory to 
chemotherapy and are fully viable to grow and produce a tumor afterwards as if no chemotherapy was 
administered [42].  
 
Figure  5. Data from Steel [27] are shown as modified. This demonstrates how a 
multipassaged animal model tumor originally showing erratic growth becomes a 
reproducible and rapidly growing tool suitable for experimental use.  
 
The other commonly used cancer model is the theory that breast cancer grows according to the 
Gompertz equation [43-47]. Gompertz was a 19
th century actuarial scientist who proposed his equation 
as a general description of population growth. This growth starts exponentially (constant doubling 
time) and gradually slows down until it ultimately reaches a limiting plateau, as shown in Figure 6. 
This is related to the Malthusian concept that the population of a city or state is ultimately limited by 
its food supply and ability to dispose of waste. Gompertzian growth is continuous, i.e., it cannot grow, 
stop, and then grow again. Gompertzian kinetics has played an important historical role in cancer 
chemotherapy and is still often cited. According to this theory, at the time of diagnosis of primary 
breast cancer, metastatic disease is as small as it ever will be in the clinical setting—thus growing as 
fast and as chemosensitive as possible. Therefore, the optimal strategy for adjuvant chemotherapy is to 
use very intensive therapy as soon as possible after surgery and then hope for the best. This idea is 
traceable to the classical experimental work of Skipper and Schabel in the 1970s [48]. Their work was 
done using multipassaged animal models with 1 or 2 day doubling times. They could cure animals if 
and only if all cancer cells were eradicated. Their papers included terms such as LD50 and LD90 to 
indicate that some chemotherapy protocols were lethally toxic to 50% or 90% of animals. The high Int. J. Environ. Res. Public Health 2009, 6          
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success of using chemotherapy to treat animal model tumors has translated into only modest benefit in 
clinical breast cancer and accompanied by significant toxicity. Perhaps this is a result of the large 
differences in growth rates between multipassaged animal tumors and breast cancer and the reliance on 
Gompertzian kinetics to guide therapy.  
I have published my findings that the entire experimental basis for Gompertzian kinetics lies in the 
1960s era Laird papers [49-54]. Laird measured growth of “19 examples of 12 different tumors of the 
rat, mouse, and rabbit” and concluded: “The pattern of growth defined by the Gompertz equation 
appears to be a general biological characteristic of tumor growth.” That is a far reaching statement 
based on only 18 rodents and one rabbit.  
Using a least square method, Laird fit a Gompertzian equation to each individual tumor. Then Laird 
compared the best fit Gompertzian curve with a simple exponential curve and concluded that the 
Gompertzian curve fit these data better than the exponential curve. However Laird used numerical 
parameters in the exponential equation that were taken from the best fit Gompertzian equation. The 
proper comparison would be a best fit Gompertzian to a separately best fit exponential.  
As a numerical example of this, for one particular tumor Laird fit W=W0 * exp [(0.788/0.142) * (1 
– exp (-0.142 t))]. That Gompertzian expression reasonably well fit those data. Then expanding  [1 – 
exp (-0.142 t)] in a Taylor series as [1 – 1 + 0.142 t - …] or 0.142 t (taking the first non-zero term), 
Laird concluded that the exponential curve to compare to the best fit Gompertzian fit is exp [0.788 t]. 
As no surprise, the pure exponential curve was accurate at t = 0 but rapidly became far larger than the 
best fit Gompertzian. This flawed analysis was conducted for each of the 19 tumors Laird reported. 
Remarkably, Gompertzian kinetics as a valid description of breast cancer growth has been virtually 
unchallenged other than from my own publications. Laird papers have been cited over 1,000 times. 
Despite that, I came to the conclusion that I was the only person who actually read these papers.  
 
Figure 6. Gompertzian growth shown as log tumor burden (as represented by number of 
cells) vs. time (days).  
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The Gompertzian growth model has long been assumed to describe primary and metastatic breast 
tumors. The growth starts as exponential (constant doubling time) which would appear as a straight 
line on this semi-log scale. Gompertzian growth is a damped exponential which means it gradually 
slows and approaches an asymptotic value. There are two parameters in this function that determine 
the initial growth rate and the ultimate size (N is the number of cells in the tumor). The equation is 
N = exp[(A/B)(1 – exp(−Bt)]. In Figure 6, A was chosen as 0.3 per day and B was chosen to be 0.008 
per day. Time t is expressed in days. At small time, N = exp(At), so A determines the slope in the early 
exponential phase. The ultimate size asymptotically attainable in Gompertzian growth is exp(A/B) and 
in this example it is 1.9 × 10
16 cells. This value must be larger than 10
12 cells, the value that is usually 
taken as a lethal tumor burden, since untreated cancer is presumed to be uniformly lethal. Thus, the 
two parameters A and B are not completely independent. 
   Gompertzian growth does not allow for dormancy. That is, the growth is continuous from a single 
cell to ultimate conclusion. In addition, it is assumed that all tumors are independent. That is, removal 
of the primary tumor is assumed to have no bearing on growth of metastatic disease according to this 
theory. Gompertzian kinetics may well describe the growth of multipassaged animal tumors especially 
if they are allowed to attain large size. The main drawback in its use to design clinical treatments stems 
from the unsupported belief that it was explanatory of “all” the natural history of tumors in the 
subclinical phase and the clinical phase. A situation such as this would never happen in physics. The 
equivalent in physics would be if no one reviewed and tested Newton’s Laws. 
 
5. Unusual Start of Breast Cancer Research Project 
 
After completing the PhD at Chicago, I worked in the electron beam technology field at Zenith 
Electronics in Chicago and Hewlett-Packard in Colorado Springs. While at Hewlett-Packard, I became 
interested in cancer research when a good friend’s wife was diagnosed with gastric lymphoma. A small 
informal research group was formed consisting of myself, Robert Wardwell (the patient’s husband and 
project organizer), Victor Petrosky, PhD (H-P scientist) and Jack Speer, MD (the medical oncologist 
treating Wardwell’s wife). We decided to study breast cancer using computer simulation since there 
was much data available for that disease and powerful H-P computers were available for our use. I did 
the computer simulation since that was my forte. 
We never had any funding and never had a leader, but there was good chemistry within the group. 
We would meet on Tuesday evenings at 7 p.m. in Speer’s office at Penrose Hospital. It would start 
with Speer and Petrosky having an argument about some philosophical point from the prior week, we 
would then discuss our project, and the meeting would end later with Speer telling a joke. 
Due to a very strange circumstance, for five years I had an engineering position at H-P that did not 
require my full attention, allowing me time to read cancer research papers from the Penrose Hospital 
Library. Rather than from formal classes or attending lectures, I learned about cancer beginning with 
the original papers. In addition, Speer was an excellent resource. With my strong educational 
background in basic science, I was able to discern where evidence was strong and where it was not. 
While evidence-based medicine is now a well established principle, it was not always so and some 
standard cancer practices were established at an earlier time. Int. J. Environ. Res. Public Health 2009, 6          
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The close involvement with Dr. Speer, who was treating patients daily, kept the group on a clinical 
perspective. We wanted to design chemotherapy protocols to better treat patients and we wanted to do 
it right then. (I must note that in addition to the original core group, in later years, other physicians and 
scientists including David Headley, Douglas Swartzendruber, Paul Bame, Romano Demicheli, 
Pinuccia Valagussa, Gianni Bonadonna, and William Hrushesky made important contributions.) 
What we thought would be a relatively modest but useful project was to build a computer 
simulation of breast cancer growth and treatment using well-established concepts of tumor growth and 
response to chemotherapy. This could then be used to study various chemotherapy protocols. Perhaps 
simple variations could make large differences in outcome. However, early difficulties were 
encountered when accepted theories of tumor growth could not be reconciled with published clinical 
data. Deciding that the theory must be revisited, a new theory of intermittent growth was proposed that 
agreed with these data. The group eventually published two papers [55, 56], proposing that cancer 
growth includes periods of dormancy rather than the accepted continuous growth Gompertzian 
kinetics. 
Gradually I became more interested in cancer research than electron optics. Cancer research seemed 
to be in a state of turmoil much like physics was before the 1920s and 1930s when atomic theory and 
quantum theory were developed. That is, there were many critical observations in cancer research and 
therapy, but seemingly there were no overarching connections tying one to another. In comparison, 
current physics research was much more mature, organized, and orderly and seemed far less exciting. 
In 1987, H-P wanted to downsize and offered voluntary severance packages. I took that and got a 
position as Research Professor in the department of Biology at the University of Colorado. I also was 
Visiting Professor alternate weeks for six months in the Department of Medicine at University of 
Texas, San Antonio, in the late William McGuire’s group. With access to a Cray supercomputer, we 
tested the accuracy of the computer simulation using UT’s 5,700 patient database and ended up with 
3–4% error. A reference laboratory in Stratford, CT, heard about the project and wanted to provide a 
prognostic report based on the computer simulation free to their tumor marker clients. My wife and I 
ended up moving to Connecticut to develop and help market the prognostic report. This activity ended 
in 1994.  
 
6. Diagnosed with Stage 3 Colon Cancer and Deciding on an Unorthodox Adjuvant Therapy 
 
This research project became more than just a theory to me when I was diagnosed with stage 3 
colon cancer in November 1994. This resulted from a change in medical insurance that triggered a 
routine physical. Fecal occult blood test (FOBT) came out positive twice and the resulting colonoscopy 
showed a large sigmoid tumor. I was awake towards the conclusion of this procedure and there was no 
doubt what was on the monitor. I knew instantly that I had colon cancer. I put everything else on hold 
and focused all my attention on my disease and how to treat it. 
Surgery to remove the primary tumor was routine. Steve Stein—a highly recommended Yale 
surgeon performed the surgery. Surgery and recovery went well but my long-term prognosis was quite 
concerning. There were four positive nodes, the tumor had penetrated the muscularis propria and into 
the pericolonic fat. In the tumor, p53 was mutated and the tumor cells were aneuploid. I looked up Int. J. Environ. Res. Public Health 2009, 6          
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relevant papers and determined that my risk of metastatic relapse was 80% without any chemotherapy 
and about 50% with conventional therapy.  
As might be expected, my scientific inclinations were against conventional short course, intensive 
chemotherapy. The last few sentences in a paper I presented in Switzerland in 1993 are: “Our studies 
suggest that (chemo) therapy is too ineffective by a factor of 2 to be considered curative. However, if 
used judiciously, these same drugs may be effective enough to retain tumors at small size. We believe 
that this is true even considering acquired drug resistance. It is like a boxer going for the decision 
rather than the knockout [57].” 
Thus, I decided against conventional 5FU—leucovorin chemotherapy. Jack Speer suggested to 
contact Bill Hrushesky who was then in Albany, NY, at the VA Hospital. After discussions with Dr. 
Hrushesky, I eventually decided to use low-dose infusional-delivered 5FU. This drug has been around 
for decades and out of patent protection, so it was very inexpensive—actually less costly than sterile 
water. This particular method of therapy had been used in late-stage disease to extend life but never 
used in adjuvant therapy—where I planned to use it. 
Hrushesky put me on 70% of the usual long-term tolerable dosage of 300 mg/m
2/day. The drug was 
given through a port-a-cath via a programmed portable pump that ran from 4 to 10 p.m. every night. 
During the other 18 hours/day, the pump went into a trickle or keep-vein-open mode [58]. Toxicity 
profiles are steep for these drugs. Reducing dosage by just 30% essentially eliminated toxicity.  
Researching low-dose infusion 5FU, I found it is useful in a wide variety of cancers and does not 
seem to develop drug resistance even over long-term use. All chemotherapy drugs develop resistance 
but, at least at that time, it was thought that antiangiogenic drugs never develop resistance. I was 
beginning to think that the mechanism of action for my therapy might be partially antiangiogenic. 
It was quite burdensome to wear the pump all the time. I then read some papers from France saying 
the optimal time for drug delivery varied somewhat from study to study. I decided that it probably 
mattered less the exact time of day the drug was used but quite important to do it every day and for a 
long time. I ended up using it only at night, starting at bedtime (whenever time that was) and running it 
for 6 hours. I would disconnect the pump every morning and flush the lines. Wearing a loose fitted 
shirt, the sub-skin port and attached short tubulation were not visible. At night, I reprogrammed the 
pump and connected it to my port. This made the protocol much easier. 
It was a lot of fussing but I stayed on this therapy virtually every night. On the basis of some 
calculations, I stopped at 2.5 years. The port was in for about 5 years and I never had a problem with it. 
I attribute that to the skill of surgeon Steve Stein. 
While still on therapy, I became part of Judah Folkman’s Lab as Lecturer in Surgery, since my 
breast cancer research dovetailed with their experimental work showing the importance of tumor 
dormancy and how angiogenesis plays a role. In December 1996, I talked to Dr. Folkman about my 
therapy and asked if they ever tested 5FU for antiangiogenic properties. He said they did and found no 
such effect. I then asked if they tried it at continuous infusion since the half-life of a large single 
injection of 5FU is about 20 min and any possible antiangiogenic effect would likely be missed. They 
had only tested 5FU as a large single injection. Dr. Folkman brought Tim Browder in the discussion. 
Browder was a pediatric medical oncologist who was doing animal experiments on chemotherapy 
drugs and testing for possible angiogenesis effects. Browder subsequently purchased micro-pumps that 
could be implanted in mice to treat using continuous infusion. They determined, to some surprise, that Int. J. Environ. Res. Public Health 2009, 6          
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continuous infusion of 5FU and other common cytotoxic drugs such as cyclophosphamide were 
partially antiangiogenic. The important aspect is to use the drug on a continuous or more frequent 
antiangiogenic schedule instead of the customary high-dose every few weeks. The vasculature 
responds but apparently recovers in the period between conventional drug applications. 
Due to the revolutionary findings, it was difficult to publish the study which was eventually 
published in April 2000 [59]. This method of therapy is now called “metronomic chemotherapy” and is 
being tested in many locales. Browder et al. has been cited over 500 times. 
This information was passed on to a colon cancer patient website long before it was published. It 
was too important to wait. Dr. Folkman was receiving many calls daily from cancer patients and their 
physicians. He referred perhaps 100 calls to me. I know many patients have used it for metastatic 
disease. My therapy is also described in 2000 in a biography of Judah Folkman by Robert Cooke [60]. 
There are three pages in that excellent book on my medical history. 
As of now, no one else to my knowledge has ever been treated with any low-dose long-term drug 
such as 5FU as an adjuvant therapy—as I used it and think it will be most effective. It is now 14 years 
since diagnosis. I am NED (no evidence of disease) and well beyond the risk of relapse time for colon 
cancer. My health is excellent and there were no short or long-term toxicities such as cognitive 
dysfunction, neuropathy, or heart disease that sometimes occur for ordinary high-dose adjuvant 
chemotherapy. (As evidence of the lack of cognitive dysfunction, the computer simulation resulting in 
the 1997 papers was conducted while I was on therapy.) By the way, Mrs. Wardwell is also fine and 
last I heard she was managing a hospice unit in Colorado Springs. 
I tried but was never able to generate any interest to start a trial or even a pilot study of this therapy. 
A big problem is that there would be no way to recoup the high expenses of pursuing this effect, since 
the drug is so inexpensive. Even though my case is well-documented, it is impossible to prove that I 
was not cured by surgery—a 20% likelihood. At any rate, I was the first person treated with 
antiangiogenic adjuvant chemotherapy. Judah Folkman has introduced me on more than one occasion 
as the first human treated with metronomic (adjuvant) chemotherapy. 
It is ironic, but dormancy, that is so common in breast cancer, is rare in colon cancer. So my 
original rationale was probably wrong, but the result turned out right for me anyway. 
 
7. Reflections and Recent Developments 
 
It is not for everyone but as an intellectual stimulation, I highly recommend a career change after 20 
years in one field. For me it has been a tonic. At an age at which most scientists are well past their 
prime, I have never been more productive.  
Among other things, I recently submitted a patent application for a new primary antiangiogenic 
treatment plan for early stage breast cancer that is non-toxic and should be far more effective than 
conventional adjuvant chemotherapy and hormone therapy. It is based on the reports [61-63] that 
women with trisomy 21 or Down syndrome (DS) have 10 to 25-fold less incidence of breast cancer 
compared to age-matched women with normal levels of chromosome 21. The endogenous 
antiangiogenic factor Endostatin is produced by genes located on chromosome 21. In view of the 
findings of the algorithm reported here, this suggests that before surgery to remove a newly diagnosed 
breast cancer, Endostatin should be increased to DS levels and kept at that high level indefinitely. Int. J. Environ. Res. Public Health 2009, 6          
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Since persons with DS have no particular wound healing problems [64], this therapy will not interfere 
with recovery after surgery and should keep any micrometastases dormant as long as the therapy is 
continued [65]. It is non-toxic and drug resistance apparently does not develop, while that cannot be 
said for chemotherapy and hormone therapy. This could be considered the breast cancer analog to the 
colon cancer therapy as described previously. 
There is a need for persons with the scientific discipline and perspective of experimental physics to 
work in cancer research. One interesting connection between detection of cancer and quantum physics 
has been pointed out by Badwe and Vaida [66] and I am sure there are more such overlaps yet to be 
discovered. There is much important work to be done in developing numerical models of cancer to 
guide scientists and physicians in research and in clinical settings. Other cancers need to be similarly 
analyzed—particularly melanoma, lung, prostate, and osteosarcoma. I would like to see 10 or more 
persons with PhD backgrounds in experimental physics doing cancer research. But they have to 
somehow or other be integrated into clinical and laboratory networks and to be sure to read the old 
literature [67].  
As a sad end-note, Judah Folkman died in January 2008 at age 74 and Tim Browder died in March 
2008 at age 51, both of sudden heart attacks. The week Dr. Folkman died, the lab personnel met at the 
regularly scheduled Friday morning meeting but instead of discussing angiogenesis, we shared 
memories. His chair was empty and the monogrammed lab coat that he always wore was draped over 
the back. During the next several hours, people just stood up and started talking about special 
memories of Judah Folkman. The picture that emerged from these often emotional comments was that 
Dr. Folkman was more than a physician, scientist, teacher, and mentor to us. He treated us like we 
were an extension of his family. He went to extreme lengths in our behalf. He would get the most 
skilled surgeon at Harvard to operate on someone’s child. He would visit someone in the hospital or he 
would call anywhere in the world to get something done or inquire about someone’s ill parent. Up until 
a few years ago, his home phone number was listed in the Boston public directory. Someone 
commented that Dr. Folkman was the only person he knew who had no hobbies. He was totally 
dedicated to helping others. Every evening he would call 10 of the cancer patients who called his 
office that day. Occasionally Judah Folkman spoke about retirement. But first he had a list of things he 
wanted to accomplish. He never told us what they were - and I have often wondered about that - but I 
am sure at least some are unfulfilled.  
Tim Browder had not been seen around the lab for perhaps the past 5 years so only a few of us “old-
timers” knew him. Tim was a dedicated and brilliant scientist and will be long remembered for his 
major contribution demonstrating what came to be called metronomic chemotherapy. 
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Note: This paper has been adapted from a manuscript submitted as an invited paper to the occasionally 
and erratically published journal Mammology several years ago. It is doubtful that Mammology will 
ever publish the manuscript, so it was modified and updated to include a discussion of the algorithmic 
approach to understanding how breast cancer develops as well as the new proposal for primary 
antiangiogenic therapy of early stage breast cancer. 
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